Most Read

The in vitro study, which was held by Pfizer and the University of Texas Medical Branch (UTMB), demonstrated that the antibodies from people subjected to the vaccine could

The company has pooled funds in a financing round co-led by new investors Rock Springs Capital and Foresite Capital. Other new investors consist of T. Rowe Price, Wellington

The phase III randomised, double-blind, placebo-controlled, two-arm, parallel-group and multi-centre study will assess safety, tolerability and clinical benefit of the company’s human recombinant alkaline phosphatase to treat patients

As per terms of the deal, Bayer will extend its support for further development, supply and crucial territory operations of CureVac´s Covid-19 vaccine candidate. By the end of

The conditional marketing authorisation is based on the recommendation of the European Medicines Agency (EMA) for use of the Covid-19 Vaccine Moderna for active immunisation to prevent Covid-19

Fujifilm stated that it is establishing the new manufacturing site to boost the growth of its biopharmaceutical contract development and manufacturing business (CDMO). The company’s subsidiary Fujifilm Diosynth

Under the deal, LakePharma will produce Akston’s adjuvanted Covid-19 vaccine candidate (AKS-452), which is slated to start phase 1/2 clinical testing later this month. LakePharma president and CEO

The breakthrough therapy designation allows the combination therapy as a first-line treatment for people with metastatic NSCLC whose tumours have high PD-L1 expression with no EGFR or ALK

Arvelle Therapeutics is involved in the development of advanced solutions to treat patients suffering from central nervous system (CNS) disorders. The company is currently engaged in the development